BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Promising Launch and Strategic Positioning Drive Buy Rating
- Alnylam price target lowered to $268 from $284 at Morgan Stanley
- Alnylam Pharma’s Strong Market Position and Growth Potential Justify Buy Rating
- Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy
- Hold Rating on Alnylam Pharma’s Qfitlia Amid FDA Approval and Market Challenges